Q3 25 EPS
$-0.92
BEAT +6.49%
Est. $-0.98
Q3 25 Revenue
$13.8M
MISS 2.41%
Est. $14.1M
vs S&P Since Q3 25
+57.1%
BEATING MARKET
NTLA +67.6% vs S&P +10.4%
Market Reaction
Did NTLA Beat Earnings? Q3 2025 Results
Intellia Therapeutics delivered a mixed but shadow-laden third quarter, with an EPS loss of $0.92 beating the $0.98 consensus by 6.49%, even as revenue of $13.78 million came in just 2.41% below estimates despite surging 51.3% year over year. The fin… Read more Intellia Therapeutics delivered a mixed but shadow-laden third quarter, with an EPS loss of $0.92 beating the $0.98 consensus by 6.49%, even as revenue of $13.78 million came in just 2.41% below estimates despite surging 51.3% year over year. The financial results, however, were overshadowed by a serious safety event in the company's lead program: a patient death linked to Grade 4 liver toxicity in the MAGNITUDE Phase 3 trial of nex-z prompted the FDA to place a clinical hold on both MAGNITUDE trials on October 29, forcing Intellia to suspend all milestone guidance for nex-z pending regulatory alignment. The narrower net loss of $101.32 million, down from $135.71 million a year ago, largely reflected a $28.70 million reduction in R&D expenses tied to scaled-back staffing and contracted services. Attention now shifts to lonvo-z for hereditary angioedema, where Phase 3 enrollment completed in September; topline data are expected by mid-2026, with a potential U.S. Launch in early 2027, supported by roughly $670 million in cash that management believes funds operations into mid-2027.
Key Takeaways
- • R&D expenses decreased by $28.7 million year-over-year, driven by lower employee-related expenses, stock-based compensation, research materials and contracted services
- • Collaboration revenue increased $4.7 million year-over-year, driven by higher cost reimbursements from Regeneron
- • Net loss narrowed to $101.3 million from $135.7 million in Q3 2024
- • Raised $114.5 million in net equity proceeds from ATM program during the quarter
NTLA YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
NTLA Revenue by Segment
With YoY comparisons, source: SEC Filings
“We were deeply saddened to learn that the patient who experienced Grade 4 liver transaminase elevations and increased total bilirubin following a dose of nex-z in the MAGNITUDE Phase 3 clinical trial, as reported on October 27, 2025, passed away last night. We have been advised by the treating physician that this is a case with complicating comorbidities, and it is being further evaluated. As we await the FDA's clinical hold letter, we are working with clinical investigators and external experts to better understand the liver-related events that have been observed within MAGNITUDE and to develop our risk mitigation plan.”
— John Leonard, Q3 2025 Earnings Press Release
NTLA Earnings Trends
NTLA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NTLA EPS Trend
Earnings per share: estimate vs actual
NTLA Revenue Trend
Quarterly revenue: estimate vs actual
NTLA Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q1 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q4 25 BEAT FY | $-0.96 | $-0.83 | +13.71% | $23.0M | +89.08% |
| FY Full Year | $-4.00 | $-3.81 | +4.75% | $67.7M | +18.53% |
| Q3 25 BEAT | $-0.98 | $-0.92 | +6.49% | $13.8M | -2.41% |
| Q2 25 BEAT | $-1.01 | $-0.98 | +2.51% | $14.2M | +17.12% |
| Q1 25 BEAT | $-1.27 | $-1.10 | +13.46% | $16.6M | +38.72% |
| Q4 24 BEAT FY | $-1.32 | $-1.27 | +3.52% | $12.9M | +58.94% |
| FY Full Year | — | $-5.25 | — | $57.9M | — |